Piscataqua Savings Bank’s Takeda Pharmaceutical TAK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$8.3K Hold
518
0.01% 356
2026
Q1
$9.59K Hold
518
0.01% 340
2025
Q4
$8.07K Hold
518
0.01% 344
2025
Q3
$7.58K Hold
518
0.01% 304
2025
Q2
$8.01K Hold
518
0.01% 301
2025
Q1
$7.7K Hold
518
0.01% 282
2024
Q4
$6.86K Hold
518
0.01% 289
2024
Q3
$7.37K Hold
518
0.01% 286
2024
Q2
$6.7K Hold
518
0.01% 283
2024
Q1
$7.2K Hold
518
0.01% 287
2023
Q4
$7.39K Hold
518
0.01% 277
2023
Q3
$8.01K Hold
518
0.01% 276
2023
Q2
$8.14K Hold
518
0.01% 276
2023
Q1
$8.53K Sell
518
-70
-12% -$1.11K 0.01% 274
2022
Q4
$9.17K Hold
588
0.01% 264
2022
Q3
$8K Hold
588
0.01% 261
2022
Q2
$8K Hold
588
0.01% 266
2022
Q1
$8K Hold
588
0.01% 277
2021
Q4
$8K Hold
588
0.01% 279
2021
Q3
$9K Hold
588
0.01% 274
2021
Q2
$10K Hold
588
0.01% 267
2021
Q1
$10K Buy
+588
New +$10.6K 0.01% 262

Other funds holding TAK

Piscataqua Savings Bank's TAK Position: Q2 2026 in Review

Piscataqua Savings Bank held its Takeda Pharmaceutical (TAK) position steady in Q2 2026 at 518 shares worth $8.3K. The position accounts for 0.01% of the portfolio, ranked #356.

Piscataqua Savings Bank first reported a position in TAK in Q1 2021 and has held it in 22 quarters since. The position peaked at $10K in Q2 2021. 77 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Piscataqua Savings Bank held 518 shares of Takeda Pharmaceutical worth $8.3K as of Q2 2026.
  • Piscataqua Savings Bank left its Takeda Pharmaceutical share count unchanged in Q2 2026.
  • Takeda Pharmaceutical made up 0.01% of Piscataqua Savings Bank's portfolio in Q2 2026, its #356 holding.
  • Piscataqua Savings Bank first reported a position in Takeda Pharmaceutical in Q1 2021 and has held it in 22 quarters since.
  • Piscataqua Savings Bank's Takeda Pharmaceutical position peaked at $10K in Q2 2021.
  • 77 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Piscataqua Savings Bank's 13F filing for Q2 2026, filed 9 Jul 2026.